Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
Two randomized, open-label, noninferiority phase 3 trials compared the prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with incident or prevalent chronic kidney disease who were undergoing dialysis. Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascul...
Saved in:
Published in: | The New England journal of medicine Vol. 384; no. 17; pp. 1601 - 1612 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Massachusetts Medical Society
29-04-2021
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Two randomized, open-label, noninferiority phase 3 trials compared the prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with incident or prevalent chronic kidney disease who were undergoing dialysis. Vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and correction and maintenance of hemoglobin concentrations. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-3 ObjectType-Feature-4 content type line 23 ObjectType-Undefined-2 |
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMoa2025956 |